最近忙着写论文，这个贴就被我这么晾着了。还有两个月我就完成大作啦，继续努力~@@！最为偷懒， 最近忙着写论文，这个贴就被我这么晾着了。还有两个月我就完成大作啦，继续努力~@@！最为偷懒，就转自己以前写过的吧。 我发现我的一篇日记总是有人收藏，尤其是最近，平均每几天就有一个人收藏，后台总是给我发来通知。 那就说明这篇帖子的内容是被人需要的，有人在搜索着。 沉默，是会呼吸的痛。我能想象到，在屏幕的那一边，有一个人正在经历着精神上的痛苦，他/她想尽力地帮助自己，不放弃一丝希望。他/她虽什么也没说，但每一天的生活都是真实地痛苦着。 我希望这个帖子能帮助有需要的人好起来。 我相信你能最终好起来。因为至少还有我这样的人，还有很多专业的人士，愿意帮助你。去认识他们，去寻求帮助，你并不孤独。 《长期抑郁该如何治疗？如何预防抑郁症复发？》 https://www.douban.com/note/576926663/ ... aizzibleoK
Patients with chronic depression (CD) by definition respond less well to standard forms of psychotherapy, so they are more likely to be high utilizers of psychiatric resources. Therefore, the aim of this guidance paper is to provide a comprehensive overview of current psychotherapy for CD. The evidence of efficacy is critically reviewed and recommendations for clinical applications and research are given. We performed a systematic literature search to identify studies on psychotherapy in CD, evaluated the retrieved documents and developed evidence tables and recommendations through a consensus process among experts and stakeholders. We developed 5 recommendations which may help providers to select psychotherapeutic treatment options for this patient group. The EPA considers both psychotherapy and pharmacotherapy to be effective in CD and recommends both approaches. The best effect is achieved by combined treatment with psychotherapy and pharmacotherapy, which should therefore be the treatment of choice. The EPA recommends psychotherapy with an interpersonal focus (e.g. the Cognitive Behavioural Analysis System of Psychotherapy [CBASP]) for the treatment of CD and a personalized approach based on the patient's preferences. The DSM-5 nomenclature of persistent depressive disorder (PDD), which includes CD subtypes, has been an important step towards a more differentiated treatment and understanding of these complex affective disorders. Apart from dysthymia, ICD-10 still does not provide a separate entity for a chronic course of depression. The differences between patients with acute episodic depression and those with CD need to be considered in the planning of treatment. Specific psychotherapeutic treatment options are recommended for patients with CD. Patients with chronic forms of depression should be offered tailored psychotherapeutic treatments that address their specific needs and deficits. Combination treatment with psychotherapy and pharmacotherapy is the first-line treatment recommended for CD. More research is needed to develop more effective treatments for CD, especially in the longer term, and to identify which patients benefit from which treatment algorithm.
Manic-depressive or bipolar depression is not as common as other forms of depression. Bipolar disorder used to be known as ‘manic depression’ because in this the person experiences periods of mania and periods of depression, with periods of normal mood in between. About 1% of the population will experience bipolar disorder at some time in their lives. In bipolar disorder cycles of mood swings from mania to depression occur over time. The mood change may have a psychotic basis with delusional thinking or occur in isolation and induce anxiety.
Brintellix通用名Vortioxetine，是一种调节和促进血清素分泌类的药物，属于非典型性抗抑郁症药物，它的机制目前还不完全清楚，但是发现它同时起到血清素再摄取抑制剂、去甲肾上腺素再摄取抑制剂、5-HT 1A受体激动剂、5-HT 1B受体部分激动剂等功能。武田制药声称，这款药物是目前唯一通过这种综合性的功能来促进血清素水平的药物，虽然每一种功能对其发挥抗抑郁作用的贡献有多大，目前为止还不是很清楚，此药除了能够改善患者的情绪外，临床研究显示还能改善认知功能，对于目前市场上销售的抗抑郁症药物来说，这可以称得上是一种具有进步性的药物。此药由武田和丹麦的灵北制药公司共同销售，在这笔交易中武田支付灵北制药4000万美元的先期付款，另外总计高达3.45亿美元的里程碑付款。2013年先后在美国和欧盟上市，预测2017年销售额8.45亿美元， 2021年销售额为17.5亿美元。